Link to this page
Biological and Environmental Research Ontology
Last uploaded:
December 23, 2022
| Id | http://purl.obolibrary.org/obo/NCIT_C64762
http://purl.obolibrary.org/obo/NCIT_C64762
|
|---|---|
| Preferred Name | Riviciclib |
| Definitions |
A flavone and cyclin dependent kinase (CDK) inhibitor with potential antineoplastic activity. Riviciclib selectively binds to and inhibits Cdk4/cyclin D1, Cdk1/cyclin B and Cdk9/cyclin T1, serine/threonine kinases that play key roles in the regulation of the cell cycle and cellular proliferation. Inhibition of these kinases leads to cell cycle arrest during the G1/S transition, thereby leading to an induction of apoptosis, and inhibition of tumor cell proliferation.
|
| Type | http://www.w3.org/2002/07/owl#Class |
All Properties
| definition | A flavone and cyclin dependent kinase (CDK) inhibitor with potential antineoplastic activity. Riviciclib selectively binds to and inhibits Cdk4/cyclin D1, Cdk1/cyclin B and Cdk9/cyclin T1, serine/threonine kinases that play key roles in the regulation of the cell cycle and cellular proliferation. Inhibition of these kinases leads to cell cycle arrest during the G1/S transition, thereby leading to an induction of apoptosis, and inhibition of tumor cell proliferation. |
|---|---|
| prefLabel | Riviciclib
|
| label | Riviciclib
|
| PDQ_Closed_Trial_Search_ID | 529362
|
| code | C64762
|
| Has_Target | |
| prefixIRI | NCIT:C64762
|
| in_subset |
See more
See less
|
| Display_Name | Riviciclib
|
| Preferred_Name | Riviciclib
|
| FDA_UNII_Code | 9EK26WE8QN
|
| Contributing_Source |
CTRP
FDA
|
| Maps_To | Riviciclib
|
| CAS_Registry | 920113-02-6
|
| NCI_Drug_Dictionary_ID | 529362
|
| Legacy Concept Name | P276
|
| type | |
| Is_Value_For_GDC_Property | |
| subClassOf | |
| PDQ_Open_Trial_Search_ID | 529362
|
| Semantic_Type |
Organic Chemical
Pharmacologic Substance
|
| UMLS_CUI | C1832023
|
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |